What is GlobeImmune, Inc. (GBIM) stock price today?

GlobeImmune, Inc. (GBIM) is currently trading at $0.00.

What is GBIM P/E ratio?

GlobeImmune, Inc.'s P/E ratio is 0.00. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is GBIM return on equity (ROE)?

GlobeImmune, Inc.'s return on equity (ROE) is -100.00%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

PNK · —

GlobeImmune, Inc. (GBIM) Stock

$0.00 PNK: GBIM —

Valuation

Metric	Value
Price	$0.00
Market Cap	—
P/E Ratio	0.00
P/B Ratio	0.00
P/S Ratio	0.00
EPS (TTM)	$-0.48
52-Week High	$0.00
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-100.00%
ROA	-25.00%
ROCE	-38.00%
Gross Margin	-50.00%
Operating Margin	-50.00%
Net Margin	-50.00%
Debt/Equity	0.00
Current Ratio	2.75

Annual Financials (USD)

Metric	2011	2012	2013	2014	2015
Revenue	$5.0M	$15.0M	$23.0M	$6.0M	$6.0M
Operating Profit	$-13.0M	$-4.0M	$8.0M	$-6.0M	$-3.0M
Net Profit	$-15.0M	$-2.0M	$9.0M	$-20.0M	$-3.0M
EPS	$-155.37	$-21.07	$-35.64	$-6.91	$-0.48
Op Margin	-246.6%	-27.1%	34.1%	-97.5%	-42.9%

Balance Sheet (USD)

Metric	2011	2012	2013	2014	2015
Total Assets	$18.0M	$4.0M	$7.0M	$18.0M	$12.0M
Total Liabilities	$200.0M	$200.0M	$207.0M	$13.0M	$9.0M
Cash	$15.0M	$2.0M	$6.0M	$17.0M	$10.0M
Borrowings	$0	$0	$0	$0	$0

Cash Flow (USD)

Metric	2011	2012	2013	2014	2015
Operating Cash Flow	$-5.0M	$-13.0M	$4.0M	$-10.0M	$-7.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$-4.0M	$0
Net Cash Flow	$-5.0M	$-13.0M	$4.0M	$11.0M	$-7.0M
Free Cash Flow	$-5.0M	$-13.0M	$4.0M	$-10.0M	$-7.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	3.84
FCF Yield	-1246163.30%
Quick Ratio	2.62
Interest Coverage	0.00
Return 1Y	0.00%
Return 3Y	-50.00%
Return 5Y	—

Ownership

Insiders Held0.00%

Institutions Held0.02%

Institutions Float Held0.02%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ANTHAnthera Pharmaceuticals, Inc.	$0.00	—	0.00	$2618	0.00%
CMRAComera Life Sciences Holdings, Inc.	$0.00	—	0.00	$3074	0.00%
FPMIFluoroPharma Medical, Inc.	$0.00	—	0.00	$6852	0.00%
IAGXImagenetix, Inc.	$0.00	—	-0.25	$5685	0.00%
NTIINeurobiological Technologies, Inc.	$0.00	—	0.00	$2702	0.00%

About GlobeImmune, Inc.

GlobeImmune, Inc., a biopharmaceutical firm based in Louisville, Colorado, and founded in 1995 (originally Ceres Pharmaceuticals, Inc. until its rebranding in May 2001), specializes in creating therapeutic products for both cancer and infectious diseases. Central to its development efforts is its unique Tarmogen platform. The company's pipeline includes several key candidates: For infectious diseases: GS-4774 is currently in Phase 2 clinical trials, designed to treat individuals chronically infected with the hepatitis B virus who are also on oral antiviral suppressive therapy. Additionally, GlobeImmune has various other infectious disease programs in the preclinical stage, such as GI-19000 for tuberculosis, GI-2010 for human immunodeficiency virus (HIV), and GI-18000 for hepatitis D virus infections. For oncology: GlobeImmune is advancing GI-6301, which targets cancers characterized by the expression of the brachyury protein. GI-6207 is progressing through Phase 2 clinical trials for medullary thyroid cancer. Furthermore, GI-4000 is a significant asset, undergoing Phase 2b clinical trials for resected pancreatic cancer, and is also in separate Phase 2 trials for non-small cell lung cancer and colorectal cancer. To support its endeavors, GlobeImmune maintains strategic alliances with industry leaders such as Gilead Sciences, Inc. and Celgene Corporation.

GlobeImmune, Inc. is led by CEO Donald Bellgrau, employs 2 people, headquartered in Louisville, US, publicly traded since 2014.

the stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, GlobeImmune, Inc. generates a return on equity (ROE) of -100.00%, return on capital employed of -38.00%, an operating margin of -50.00%, a net profit margin of -50.00%.

Official website: www.globeimmune.com